The Good & Well Pharmacy, a Medicaid provider of outpatient drugs, is subject to the prospective drug utilization review (DUR) mandates of the Omnibus Budget Reconciliation Act of 1990 (OBRA '90). One component of prospective DUR is screening. In this context, when Good & Well is involved in the process of screening, the pharmacy is

Question

Quizplus · Accepted Answer

Screening in the context of prospective DUR refers to the process of reviewing patient profiles to identify potential problems, such as drug interactions or therapeutic duplications. This is an important component of ensuring safe and effective use of medications, especially in Medicaid populations who may be at higher risk for adverse drug events. Updating a formulary (A) and consulting directly with prescribers and patients (C) are other important activities related to medication management, but they are not specifically related to screening in the context of prospective DUR. Denying coverage for off-label use (D) is not necessarily part of prospective DUR, although Medicaid programs may have policies in place to restrict coverage for certain off-label uses.

The Good & Well Pharmacy, a Medicaid Provider of Outpatient